Abstract:
Current efforts to prevent dyslipidemia are focused on the development of functional products as an alternative for hypertriglyceridemia management. This study assessed the metabolic effect of the daily consumption of a bean and oats snack bar (BOSB) on hypertriglyceridemia biomarkers among Mexican women. An 8-weeks randomized parallel clinical trial (ID: NCT0496694, https://clinicaltrials.gov/ct2/show/NCT04966494) was conducted with 26 hypertriglyceridemic women allocated to BOSB group (TG = 208.18 ± 56.97 mg/dL) and control group (TG = 182.28 ± 51.39 mg/dL). Only the BOSB group consumed 50 g of the product per day. Fasting blood samples were taken from women with an adherence ≥ 90%. A targeted proteomic analysis with plasma samples of control and BOSB groups were conducted using a human obesity antibody array kit and bioinformatic tools provided by the Ingenuity Pathways Analysis (IPA) software. Serum TG levels in the BOSB group decreased by 37.80% (132.04 ± 27.83 mg/dL) compared with the control group (178.87 ± 32.01 mg/dL); glucose levels decreased by 5.69% in the BOSB group (87.55 ± 3.36 mg/dL). A modest body weight (5%) reduction was also found. Forty proteins were differentially modulated by the BOSB consumption (fold change > 1.2). The proteomic analysis revealed the involvement of BOSB bioactives in prevention of monocytes recruitment and localized inflammatory response, inhibition of pre-adipocyte maturation and adipogenesis, inhibition of hepatic b-oxidation, and potential satiety regulation. These results are promising since the mere intervention with the BOSB reduced serum TG without diet restriction, giving insights for further research in prevention of hypertriglyceridemia.
摘要:
目前预防血脂异常的努力集中在开发功能性产品作为高甘油三酯血症管理的替代方案。这项研究评估了墨西哥女性每天食用豆类和燕麦小吃店(BOSB)对高甘油三酯血症生物标志物的代谢影响。进行了为期8周的随机平行临床试验(ID:NCT0496694,https://clinicaltrials.gov/ct2/show/NCT04966494),其中26名高甘油三酯女性被分配到BOSB组(TG=208.18±56.97mg/dL)和对照组(TG=182.28±51.39mg/dL)。仅BOSB组每天消耗50g的产品。空腹血液样本取自依从性≥90%的女性。使用人肥胖抗体阵列试剂盒和由Ingenuity途径分析(IPA)软件提供的生物信息学工具,对对照和BOSB组的血浆样品进行靶向蛋白质组学分析。与对照组(178.87±32.01mg/dL)相比,BOSB组血清TG水平下降37.80%(132.04±27.83mg/dL);BOSB组血糖水平下降5.69%(87.55±3.36mg/dL)。还发现适度的体重(5%)减少。40种蛋白质被BOSB消耗差异调节(倍数变化>1.2)。蛋白质组学分析显示BOSB生物活性物质参与预防单核细胞募集和局部炎症反应。抑制前脂肪细胞成熟和脂肪形成,抑制肝脏b-氧化,和潜在的饱腹感调节。这些结果是有希望的,因为仅仅用BOSB干预降低了血清TG而没有饮食限制,为预防高甘油三酯血症的进一步研究提供见解。